Sm-153 decays by beta emission and gamma emission with a half-life of 1.93 days. It is typically produced in nuclear reactors by neutron irradiation of samarium-152. The resulting Sm-153 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of nuclear reactors, samarium targets, and radiochemistry facilities. Logistical challenges include the transport and handling of radioactive materials. Accessibility for developing countries is influenced by the specialised facilities and regulatory requirements.
Overview
Maturity
Sm-153 production and application are well-established, with use in palliative radiation therapy.
Safety considerations
I-123 is a radioactive isotope that emits beta and gamma radiation, requiring careful handling procedures and physical shielding to minimise radiation exposure.
Security considerations
All radioactive isotopes can be misused, and as such, robust security protocols around chain of custody, inventory management, and physical security are critical.
Safeguarding considerations
Due to the absence of nuclear materials, IAEA safeguards are not applicable.
